Hand, foot and mouth disease （HFMD） has become a major public health problem in China since 2008,which has been widely prevalent in children under 5 years of age. According to the data of the Ministry of Health, the...Hand, foot and mouth disease （HFMD） has become a major public health problem in China since 2008,which has been widely prevalent in children under 5 years of age. According to the data of the Ministry of Health, the number of cases with HFMD exceeded 1 million during the recent 4 years. The major etiologic agent of HFMD is enterovirus 71 and coxsackievirus A 16. The main clinical manifestations of the disease include fever, maculopapular skin vesicles on the hand, foot and buttock, oral herpes, ulcer; ation severe cases there can be central nervous system infection and/or pulmonary hemorrhage, which are mostly caused by EV71 and may be life-threatening with a fatality rate of 0.3 to 0.5 per thousand cases. There are no specific antiviral drugs, nor vaccine against EV71.~ The difficult problem of the treatment is how to reduce the severe cases and mortality. Reduning injection is a preparation of traditional Chinese herbal medicine composed of Qinghao （Artemisiae annuae）, Jinyinhua （Flos lonicerae） and Zhizi （Gardenia jasminoides）, which was listed among the therapies for HFMD in the 2010 guidelines of the Ministry of Health for diagnosis and treatment of HFMD.2 We now reported the results of our study on the efficacy of Reduning injection in treatment of 81 patients with HFMD. We selected 81 cases who were inpatients treated in 2010 in the Department of Infectious Diseases of Quanzhou Chidren＇s Hospital. The inclusion criteria were as follows： 1. Patients who met either the clinical diagnostic criteria for HFMD ordinary clinical type or the clinical diagnostic criteria for confirmed cases of HFMD （etiologically confirmed cases must account for more than 1/3 of the cases）. 2. The axillary temperature is _〉37.5~C, within 48 hours after onset of the disease; 3. Skin changes such as the rashes and vesicles occurred in no more than 48 hours; 4. Range of age is between 1 and 13 years; 5. Patients or their parents or guardians are willing to participate in the study and sign the informed consent forms. The exclusion criteria were as follows： 1. Patients who are complicated with the following primary diseases： congenital heart disease, chronic hepatitis, acute or chronic nephritis, diseases of hematologic system; 2. Patients who have hypersensitivity with history of allergy to the study drugs or other drugs; 3. Patients who were treated with western or traditional Chinese medicines other than the study medicines for HFMD by the time of the visit to the hospital; 4. Patientswho have been participated in other clinical trial for HFMD. The patients were centrally randomized （the random numbers were obtained from the web version of the Randomization System of Clinical Studies, Clinical Evaluation Center of Chinese Academy of Traditional Chinese Medicine, No. 200907001-3） into the following 3 groups： Reduning group （group 1）, 28 cases with 21 men and 7 women; age 12-72 （mean 29.2＋18.8） months; 24 were positive for EV71, 2 were positive for CoxA16 and 2 were negative for both; treated with intravenous infusion of Reduning （Jiangsu Kangyuan Pharmaceutical Corporation, Ltd., 10 ml in each vial, Batch number 100122） at a dose of 0.5 ml.kg-＇.d＂ added into 10% glucose solution for injection, once a day. Symptomatic treatment group （group 2）, 27 cases with 19 male and 8 female; age 12-96 （mean 28.7＋20.4） months; 19 were positive for EV71, 3 were positive for CoxA16 and 5 were negative for both; these patients were treated with intravenous infusion of vitamin C （0.5-1.0 g/d） and B6 （50-100 mg/d） added into 10% glucose solution for injection and ibuprofen （5-10 mg/kg per day, 6-8 hours repeat p.r.n.） or Aspisol （15-25 mg＇kg＂.d1） was used for antipyretic purpose. Antibiotics were added for patients who had increased peripheral blood leukocyte count. And Reduning plus symptomatic treatment group （group 3）, had 26 cases with 17 male and 9 female; age 12-84 （mean 30.4＋16.6） months; 18 were positive for EV71, 4 were positive for CoxA16 and 5 were negative for both viruses; these cases were treated with both Reduning and symptomatic treatments. No significant difference was found among the 3 groups in age, sex and etiological characteristics compared using chi-square test （P 〉0.05）. The numbers of patients who were positive for EV7I or CoxA 16 accounted for 75.3% and 11.1% for each group.展开更多
文摘Hand, foot and mouth disease （HFMD） has become a major public health problem in China since 2008,which has been widely prevalent in children under 5 years of age. According to the data of the Ministry of Health, the number of cases with HFMD exceeded 1 million during the recent 4 years. The major etiologic agent of HFMD is enterovirus 71 and coxsackievirus A 16. The main clinical manifestations of the disease include fever, maculopapular skin vesicles on the hand, foot and buttock, oral herpes, ulcer; ation severe cases there can be central nervous system infection and/or pulmonary hemorrhage, which are mostly caused by EV71 and may be life-threatening with a fatality rate of 0.3 to 0.5 per thousand cases. There are no specific antiviral drugs, nor vaccine against EV71.~ The difficult problem of the treatment is how to reduce the severe cases and mortality. Reduning injection is a preparation of traditional Chinese herbal medicine composed of Qinghao （Artemisiae annuae）, Jinyinhua （Flos lonicerae） and Zhizi （Gardenia jasminoides）, which was listed among the therapies for HFMD in the 2010 guidelines of the Ministry of Health for diagnosis and treatment of HFMD.2 We now reported the results of our study on the efficacy of Reduning injection in treatment of 81 patients with HFMD. We selected 81 cases who were inpatients treated in 2010 in the Department of Infectious Diseases of Quanzhou Chidren＇s Hospital. The inclusion criteria were as follows： 1. Patients who met either the clinical diagnostic criteria for HFMD ordinary clinical type or the clinical diagnostic criteria for confirmed cases of HFMD （etiologically confirmed cases must account for more than 1/3 of the cases）. 2. The axillary temperature is _〉37.5~C, within 48 hours after onset of the disease; 3. Skin changes such as the rashes and vesicles occurred in no more than 48 hours; 4. Range of age is between 1 and 13 years; 5. Patients or their parents or guardians are willing to participate in the study and sign the informed consent forms. The exclusion criteria were as follows： 1. Patients who are complicated with the following primary diseases： congenital heart disease, chronic hepatitis, acute or chronic nephritis, diseases of hematologic system; 2. Patients who have hypersensitivity with history of allergy to the study drugs or other drugs; 3. Patients who were treated with western or traditional Chinese medicines other than the study medicines for HFMD by the time of the visit to the hospital; 4. Patientswho have been participated in other clinical trial for HFMD. The patients were centrally randomized （the random numbers were obtained from the web version of the Randomization System of Clinical Studies, Clinical Evaluation Center of Chinese Academy of Traditional Chinese Medicine, No. 200907001-3） into the following 3 groups： Reduning group （group 1）, 28 cases with 21 men and 7 women; age 12-72 （mean 29.2＋18.8） months; 24 were positive for EV71, 2 were positive for CoxA16 and 2 were negative for both; treated with intravenous infusion of Reduning （Jiangsu Kangyuan Pharmaceutical Corporation, Ltd., 10 ml in each vial, Batch number 100122） at a dose of 0.5 ml.kg-＇.d＂ added into 10% glucose solution for injection, once a day. Symptomatic treatment group （group 2）, 27 cases with 19 male and 8 female; age 12-96 （mean 28.7＋20.4） months; 19 were positive for EV71, 3 were positive for CoxA16 and 5 were negative for both; these patients were treated with intravenous infusion of vitamin C （0.5-1.0 g/d） and B6 （50-100 mg/d） added into 10% glucose solution for injection and ibuprofen （5-10 mg/kg per day, 6-8 hours repeat p.r.n.） or Aspisol （15-25 mg＇kg＂.d1） was used for antipyretic purpose. Antibiotics were added for patients who had increased peripheral blood leukocyte count. And Reduning plus symptomatic treatment group （group 3）, had 26 cases with 17 male and 9 female; age 12-84 （mean 30.4＋16.6） months; 18 were positive for EV71, 4 were positive for CoxA16 and 5 were negative for both viruses; these cases were treated with both Reduning and symptomatic treatments. No significant difference was found among the 3 groups in age, sex and etiological characteristics compared using chi-square test （P 〉0.05）. The numbers of patients who were positive for EV7I or CoxA 16 accounted for 75.3% and 11.1% for each group.
